1. Home
  2. TBPH vs SWBI Comparison

TBPH vs SWBI Comparison

Compare TBPH & SWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • SWBI
  • Stock Information
  • Founded
  • TBPH 2013
  • SWBI 1852
  • Country
  • TBPH United States
  • SWBI United States
  • Employees
  • TBPH N/A
  • SWBI N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • SWBI Ordnance And Accessories
  • Sector
  • TBPH Health Care
  • SWBI Industrials
  • Exchange
  • TBPH Nasdaq
  • SWBI Nasdaq
  • Market Cap
  • TBPH 464.5M
  • SWBI 429.0M
  • IPO Year
  • TBPH N/A
  • SWBI N/A
  • Fundamental
  • Price
  • TBPH $10.92
  • SWBI $8.73
  • Analyst Decision
  • TBPH Strong Buy
  • SWBI Buy
  • Analyst Count
  • TBPH 5
  • SWBI 2
  • Target Price
  • TBPH $16.60
  • SWBI $12.00
  • AVG Volume (30 Days)
  • TBPH 366.7K
  • SWBI 1.2M
  • Earning Date
  • TBPH 08-04-2025
  • SWBI 06-18-2025
  • Dividend Yield
  • TBPH N/A
  • SWBI 5.95%
  • EPS Growth
  • TBPH N/A
  • SWBI N/A
  • EPS
  • TBPH N/A
  • SWBI 0.30
  • Revenue
  • TBPH $65,266,000.00
  • SWBI $474,661,000.00
  • Revenue This Year
  • TBPH $43.18
  • SWBI $8.53
  • Revenue Next Year
  • TBPH N/A
  • SWBI N/A
  • P/E Ratio
  • TBPH N/A
  • SWBI $29.12
  • Revenue Growth
  • TBPH 6.11
  • SWBI N/A
  • 52 Week Low
  • TBPH $7.44
  • SWBI $8.38
  • 52 Week High
  • TBPH $11.82
  • SWBI $16.85
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 60.52
  • SWBI 35.82
  • Support Level
  • TBPH $10.46
  • SWBI $8.55
  • Resistance Level
  • TBPH $11.44
  • SWBI $8.91
  • Average True Range (ATR)
  • TBPH 0.27
  • SWBI 0.29
  • MACD
  • TBPH -0.01
  • SWBI -0.17
  • Stochastic Oscillator
  • TBPH 56.65
  • SWBI 10.50

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

Share on Social Networks: